Main Article Content
Once an article was published in the journal, the author(s) are: granted to the journal right licensed under Creative Commons License Attribution that allows others to share the work with an acknowledgement of the work's authorship. permitted to publish their work online in third parties as it can lead wider dissemination of the work. continue to be the copyright owner and allow the journal to publish the article with the CC BY-NC-SA license receiving a DOI (Digital Object Identifier) of the work.
2. Baldo BA, Rose MA. The anaesthetist, opioid analgesic drugs, and serotonin toxicity: a mechanistic and clinical review. BJA, 2020;124 (1): 44-62.
3. Rastogi R et al. Case Scenario: Opioid Association with Serotonin Syndrome Implications to the Practitioners. Am Society of Anesth, 2011;115:1291– 8.
4. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352:1112-20.
5. Buckley NA, Dawson AH, Isbister GK. Serotonin syndrome. BMJ. 2014;348:g1626.
6. Culbertson VL, Rahman SE, Bosen GC, Caylor ML, Echevarria MM, Xu D. Implications of off-target serotoninergic drug activity: an analysis of serotonin syndrome reports using a systematic bioinformatics approach. Pharmacotherapy. 2018;38:888-898.
7. Saper CB. Brainstem modulation of sensation, movement, and consciousness. In: Kandel ER, Schwartz JH, Jessell TM, eds. Principles in Neural Science. 4th ed. New York: McGraw-Hill; 2000:896.
8. Isbister GK, Buckley NA: The pathophysiology of serotonin toxicity in animals and humans: Implications for diagnosis and treatment. Clin Neuropharmacol 2005; 28:205–14.
9. Pilgrim JL, Gerostamoulos D, Drummer OH: Review: Pharmacogenetic aspects of the effect of cytochrome P450 polymorphisms on serotonergic drug metabolism, response, interactions, and adverse effects. Forensic Sci Med Pathol. 2011; 7:162– 84.
10. Gillman PK: Serotonin syndrome: History and risk. Fundam Clin Pharmacol 1998; 12:482–91.
11. Ables AZ, Nagubilli R: Prevention, recognition, and management of serotonin syndrome. Am Fam Physician 2010; 81:1139 – 42.
12. Ener RA, Meglathery SB, Van Decker WA, Gallagher RM: Serotonin syndrome and other serotonergic disorders. Pain Med 2003; 4:63–74
13. Radomski JW, Dursun SM, Reveley MA, Kutcher SP: An exploratory approach to the serotonin syndrome: An update of clinical phenomenology and revised diagnostic criteria. Med Hypotheses 2000; 55:218 –24
14. Summary safety review-serotonin blocking drugs (serotonin antagonists) Aloxi (palonosetron), Anzemet (dolasetron), Kytril(granisetron) and generics, and Zofran (ondansetron) and generics- Serotonin Syndrome. Available at: http://www.hc-sc.gc.ca/ dhp-mps/medeff/advisories-avis/review-examen/serotonin-eng.php. Accessed May 29th 2014.
15. WHO pharmaceutical newsletter: ondansetron and serotonin syndrome. 2012;3:16–21.